Prolonged midazolam elimination half-life.
The pharmacokinetics of a fixed dose of midazolam (0.3 mg kg-1 i.v.) were studied in detail in 115 healthy patients or volunteers and nine were found with a prolonged elimination half-life. A further 102 patients had an abbreviated pharmacokinetic study, of whom five showed a similar abnormality. Defective hepatic metabolism of midazolam may be a factor in the aetiology of what appears to be a true phenomenon, occurring in 6% of over 200 fit subjects given a standard dose of the drug.
D001569:Benzodiazepines / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D004341:Drug Evaluation; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008657:Metabolic Clearance Rate; D008874:Midazolam
D001569:Benzodiazepines; D008874:Midazolam